Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$2.44 USD
-0.01 (-0.41%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.44 USD
-0.01 (-0.41%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
5 Stocks with Solid Track Records at Attractive Prices
by Sejuti Banerjea
This is probably the time to focus on fundamentals because we don't want to overpay for stocks in a buoyant market.
Surging Earnings Estimates Signal Upside for Harvard Bioscience (HBIO) Stock
by Zacks Equity Research
Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harvard Bioscience (HBIO) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harvard Bioscience (HBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Harvard Bioscience (HBIO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 66.67% and 6.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Drab Near-Term Prospects for Scientific Instruments Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is witnessing a slump in demand for instruments as laboratories and research facilities remain closed in the wake of the pandemic predicament.
Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 of the Best Stocks to Buy for a Post-Pandemic Rally
by Tirthankar Chakraborty
The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.
Scientific Instruments Industry Outlook: Prospects Look Good
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is benefiting from solid prospects in emerging markets, robust end-market demand and increasing spending on health care.
Harvard Bioscience Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.
Why Harvard Bioscience (HBIO) Might be Well Poised for a Surge
by Zacks Equity Research
Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harvard Bioscience (HBIO) Matches Q3 Earnings Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and -3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) to Report Q3 Results: What Awaits?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Q2 Earnings Match Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 0.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Harvard Bioscience (HBIO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -33.33% and -0.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience (HBIO) Meets Q3 Earnings Estimates
by Zacks Equity Research
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 0.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: BG, Harvard Bioscience, Vertex Energy, Hallmark and Summer Infant
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BG, Harvard Bioscience, Vertex Energy, Hallmark and Summer Infant
Small Firms Break 35-Year Record Set in Reagan Era: 5 Picks
by Tirthankar Chakraborty
Small businesses continue to benefit from tax cuts and regulatory roll backs by the White House.
Is Harvard Bioscience (HBIO) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Is (HBIO) Outperforming Other Computer and Technology Stocks This Year?